Barclays Maintains Overweight on Medline, Lowers Price Target to $43

Benzinga Newsdesk www.benzinga.com Negative 90.2%

Neg 90.2% Neu 0% Pos 0%

Barclays analyst Glen Santangelo maintains Medline (NASDAQ:MDLN) with a Overweight and lowers the price target from $45 to $43.